About Phase Genomics
Phase Genomics is a company based in Seattle (United States) founded in 2015.. Phase Genomics has raised $5.75 million across 19 funding rounds from investors including NIH, Gates Foundation and HHS. Phase Genomics offers products and services including CytoTerra Platform, ProxiMeta Platform, and Proximo Platform. Phase Genomics operates in a competitive market with competitors including Candel Therapeutics, StrideBio, Tessera Therapeutics, Genedit and Genenta Science, among others.
- Headquarter Seattle, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Phase Genomics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$5.75 M (USD)
in 19 rounds
-
Latest Funding Round
$1.5 M (USD), Grant
Mar 05, 2024
-
Investors
NIH
& 8 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Phase Genomics
Phase Genomics offers a comprehensive portfolio of products and services, including CytoTerra Platform, ProxiMeta Platform, and Proximo Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Tool for cytogenetics analysis and chromosomal abnormality detection
Platform for metagenome deconvolution and microbial host attribution
System for ultra-long-range genome mapping and analysis
Unlock access to complete
Unlock access to complete
Funding Insights of Phase Genomics
Phase Genomics has successfully raised a total of $5.75M across 19 strategic funding rounds. The most recent funding activity was a Grant round of $1.5 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 19
- Last Round Grant — $1.5M
-
First Round
First Round
(12 Jun 2016)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2024 | Amount | Grant - Phase Genomics | Valuation |
investors |
|
| Sep, 2023 | Amount | Grant - Phase Genomics | Valuation |
investors |
|
| Aug, 2023 | Amount | Grant - Phase Genomics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Phase Genomics
Phase Genomics has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Gates Foundation and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Climate tech investing and support for early-stage entrepreneurs in North America.
|
Founded Year | Domain | Location | |
|
Early-stage investments are made in Washington-based startups by WRF Capital.
|
Founded Year | Domain | Location | |
|
Charitable foundation investments on poverty reduction and healthcare
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Phase Genomics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Phase Genomics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Phase Genomics Comparisons
Competitors of Phase Genomics
Phase Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Candel Therapeutics, StrideBio, Tessera Therapeutics, Genedit and Genenta Science, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Viral immunotherapies are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
AAV-based gene therapies for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
New genome engineering technology is provided for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Genetic medicines are delivered using polymer nanoparticle platforms.
|
|
| domain | founded_year | HQ Location |
Lentivirus-based gene and cell therapies for cancer are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Phase Genomics
Frequently Asked Questions about Phase Genomics
When was Phase Genomics founded?
Phase Genomics was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Where is Phase Genomics located?
Phase Genomics is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Is Phase Genomics a funded company?
Phase Genomics is a funded company, having raised a total of $5.75M across 19 funding rounds to date. The company's 1st funding round was a Grant of $2.5M, raised on Jun 12, 2016.
What does Phase Genomics do?
Provider of laboratory and computational services and products. The company has developed technology that allows the extraction of information regarding the physical proximity of DNA stretches inside the nucleus from short- or long-read HT sequencing allowing researchers to reconstruct the 3D organization of DNA within the nucleus. Phase Genomics Proximo Hi-C measures the proximity of DNA in vivo and uses that information to scaffold contigs into entire chromosomes, or to deconvolute metagenomes from complex mixtures of environmental DNA.
Who are the top competitors of Phase Genomics?
Phase Genomics's top competitors include Tessera Therapeutics, Genenta Science and Genedit.
What products or services does Phase Genomics offer?
Phase Genomics offers CytoTerra Platform, ProxiMeta Platform, and Proximo Platform.
Who are Phase Genomics's investors?
Phase Genomics has 9 investors. Key investors include NIH, Gates Foundation, HHS, National Cancer Institute, and NHGRI.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.